Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...

Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Pfizer and Tris Pharma agreed to pay $41.5 million to settle allegations they altered testing methods to ensure their ADHD ...

A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...

The German biopharmaceutical company BioNTech finds itself at a critical juncture following a significant divestment by its ...

Anonymized data shared with pharma will remain hidden from public after two-year legal battle, based on hidden evidence of "triangulating" the deceased's identities and assumption their relatives ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...